Trial Profile
A phase II study of the efficacy and safety of irinotecan (Campto) in combination with capecitabine (Xeloda) as first-line chemotherapy in Asian subjects with inoperable hepatocellular carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Apr 2008
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Capecitabine
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 03 Apr 2008 New trial record.